Table 1:
Basal clinicopathological characteristics of the cohort and relapse data
| Overall | Class 1 Low risk | Class 2 High risk | p value | |
|---|---|---|---|---|
| n | 86 | 53 | 33 | - |
| Follow-up time | ||||
| median (IQR) | 26 (22–30) | 27 (23–32) | 24 (20–29) | 0.066 |
| Sex | ||||
| male | 40 (46.5%) | 21 (40%) | 19 (58%) | 0.105 |
| female | 46 (53.5%) | 32 (60%) | 14 (42%) | |
| Age | ||||
| median (IQR) | 59.2 (47–72) | 57 (46–68) | 68 (55–74) | 0.025 |
| Localization | ||||
| Acral | 5 (6%) | 2 (4%) | 3 (9%) | 0.738 |
| Head and neck | 11 (13%) | 7 (13%) | 4 (12%) | |
| Legs | 21 (24%) | 15 (28%) | 6 (18%) | |
| Arms | 12 (14%) | 7 (13%) | 5 (15%) | |
| Trunk | 37 (43%) | 22 (41%) | 15 (45%) | |
| Breslow | ||||
| Mean (SD) | 2.5 (2.3) | 1.7 (1.4) | 3.7 (2.9) | < 0.001 |
| ≤1.00 mm | 18 (21%) | 17 (32%) | 1 (3%) | < 0.001 |
| 1.00–2.00 mm | 33 (38%) | 23 (43%) | 10 (30%) | |
| 2.01–4.00 mm | 22 (26%) | 10 (19%) | 12 (36%) | |
| >4.00 4 mm | 13 (15%) | 3 (6%) | 10 (30%) | |
| Mitotic rate (mm2) | ||||
| <1 mm2 | 9 (11%) | 6 (11%) | 3 (9%) | 0.684 |
| ≥1 mm2 | 76 (88%) | 46 (87%) | 30 (91%) | |
| N.A. | 1 (1%) | 1 (2%) | 0 | |
| Ulceration | ||||
| Absent | 60 (70%) | 51 (96%) | 9 (27%) | < 0.001 |
| Present | 26 (30%) | 2 (4%) | 24 (73%) | |
| AJCC stage | ||||
| Low-risk (IB-IIA) | 62 (72%) | 48 (91%) | 14 (42% | < 0.001 |
| High-risk (IIB-IIC) | 24 (28%) | 5 (9%) | 19 (58%) | |
| Relapse | ||||
| No | 79 (91%) | 53 (100%) | 26 (79%) | < 0.001 |
| Yes | 7 (9%) | 0 | 7 (21%) | |
| Relapse site (n=7) | ||||
| Skin | - | 0 | 2 (29%) | - |
| Lymph node | - | 0 | 2 (29%) | |
| Visceral | - | 0 | 3 (43%) |
Abbreviations: AJCC, American Joint Committee on Cancer; IQR, Interquartile range; N.A., Not Available; SD, Standard Deviation.